LCM
PDSB icon

Laurion Capital Management’s PDS Biotechnology PDSB Stock Holding History

Laurion Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-62,901
Closed -$789K – 827
2021
Q2 		$789K Buy
+62,901
New +$491K ﹤0.01% 464

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Laurion Capital Management's PDSB Position: Q3 2021 in Review

Laurion Capital Management sold out of PDS Biotechnology (PDSB) in Q3 2021, closing a stake of 62,901 shares — an estimated $789K sold.

Laurion Capital Management first reported a position in PDSB in Q2 2021 and held it in 1 quarter. The position peaked at $789K in Q2 2021. 59 funds tracked by Wall St. Rank hold PDSB as of Q3 2021.

  • Laurion Capital Management reported no remaining PDS Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Laurion Capital Management sold 62,901 PDS Biotechnology shares in Q3 2021, an estimated $789K.
  • Laurion Capital Management first reported a position in PDS Biotechnology in Q2 2021 and held it in 1 quarter.
  • Laurion Capital Management's PDS Biotechnology position peaked at $789K in Q2 2021.
  • 59 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2021.

Based on Laurion Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.